38
Participants
Start Date
February 22, 2017
Primary Completion Date
November 15, 2020
Study Completion Date
November 15, 2020
High-dose: RIF, INH, PZA, EMB
high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
High dose: RIF, INH, PZA, LEVO
high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
Standard of care: RIF, INH, PZA, EMB
standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
Byramji Jeejeebhoy Government Medical College and Sassoon Hospital, Pune
National Institute of Research in TB and Institute of Child Health, Chennai
UNC Project- Malawi, Lilongwe
National Institute for Research in Tuberculosis, Chennai, India
UNKNOWN
University of North Carolina
OTHER
B. J. Medical College, Pune
OTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Johns Hopkins University
OTHER